During the definition of the implementation plan fo
r WHO and the corresponding M&E
framework, other output indicators were identified.
WHO is responsible for measuring and reporting acco
rding to the indicators and the timeline, as
explicited in the lower part of the graph above. Gi
ven the nature of the reporting required by the
Member States (progress in the implementation of th
e global strategy, whose stakeholders are
governments, international intergovernmental organi
zations, NGOs, pharmaceutical industry,
academia etc.) information needs to be made availab
le to PHI in order for WHO to be able to
analyse it and compile the reports.
The timeframe set for the global strategy limits th
e need and effectiveness of impact assessment,
however PHI will develop new thinking on how to mea
sure access and innovation starting from
the two indicators currently used as a proxy:
1) Access to medicines index from
MDG Target 8.E:
In cooperation with pharmaceutical
companies, provide access to affordable essential d
rugs in developing countries, indicator 8.13
Proportion of population with access to affordable
essential drugs on a sustainable basis
2) Nr of new chemical entities (NCE) for type II an
d III diseases and specific type I diseases
affecting DC.
As mentioned before, PHI has already set up a proce
ss to refine the indicators, through internal
consultations. The draft list of the new or modifie
d indicators will be shared with the GSPA-PHI
stakeholders in order to reach consensus on it. How
ever, for each of the progress (outputs) and
outcome indicators (including those approved by the
WHA in 2009) the following information is
provided to complete the framework: